OrthoPediatrics focuses on pediatric orthopedics, offering implants, instruments, and braces in the U.S. and more than 75 international markets. The third-quarter numbers provide a useful checkpoint on whether the company can sustain double-digit revenue growth while moving closer to profitability. Management has targeted roughly $25 million in adjusted EBITDA and breakeven free cash flow for 2026, so each quarter’s margin and cash-flow trends offer important signals. The record adjusted EBITDA and raised outlook suggest the specialty bracing approach and recent product launches are starting to improve operating leverage. I also checked comparable names in the space using Tickeron’s AI Screener to see how the metrics stack up.
Revenue reached $72.7 million, a 19% increase from $61.2 million in the same quarter last year. U.S. revenue grew 19% to $57.9 million, and international revenue rose 18% to $14.8 million. Trauma and Deformity revenue increased 19% to $52.6 million, while Scoliosis revenue advanced 18% to $19.2 million. Gross profit came in at $54.0 million for a 74% gross margin. Adjusted EBITDA hit a record $6.9 million versus $6.2 million a year earlier. Free cash flow improved to a positive $1.6 million from a $3.4 million use of cash in the prior-year period. The net loss narrowed to $5.9 million, or $0.25 per share, from $11.8 million, or $0.50 per share.
On a non-GAAP basis the loss was $0.23 per share, matching expectations. Revenue exceeded the consensus estimate of roughly $68.5 million by about $4.2 million. Full-year 2026 revenue guidance was lifted to a range of $270.0 million to $273.0 million, implying 14% to 16% growth, while the company reiterated its target of approximately $25 million in adjusted EBITDA and breakeven free cash flow. From what I see, the combination of the beat and the raised outlook points to steady execution.
Shares moved higher in after-hours trading, with early indications of a roughly 6% gain on the revenue beat and guidance increase. The stock has outperformed the broader Nasdaq so far in 2026, reflecting optimism about the path to profitability. Sentiment before the report had been cautiously constructive, centered on whether adjusted EBITDA would track toward the $25 million annual goal. The record quarterly result appears to have provided reassurance that growth initiatives are translating into better leverage.
Looking ahead, several items will be worth watching. The updated revenue range sets a clear target for the fourth quarter. Continued expansion in adjusted EBITDA and progress toward breakeven free cash flow will remain central. Growth in the Trauma and Deformity and Scoliosis segments, plus further rollout of specialty bracing clinics, should indicate whether momentum holds. International results outside Latin and South America are another area to monitor, as are cash and liquidity levels. New product launches and set deployments will also influence both top-line growth and capital decisions.
I often turn to Tickeron’s AI Screener when evaluating names like this one. It helps filter for technical patterns, fundamentals, and performance metrics across thousands of stocks and ETFs, making it easier to spot comparable ideas and track shifting conditions without manual effort. The tool has become a regular part of how I cross-check sector trends and identify potential follow-ups.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The 10-day RSI Oscillator for KIDS moved out of overbought territory on November 12, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 instances where the indicator moved out of the overbought zone. In 19 of the 21 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
The Momentum Indicator moved below the 0 level on November 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KIDS as a result. In 70 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
The Moving Average Convergence Divergence Histogram (MACD) for KIDS turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 35 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KIDS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
KIDS broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 52 of 67 cases where KIDS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
KIDS moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for KIDS crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 56%.
Following a +3.50% 3-day Advance, the price is estimated to grow further. Considering data from situations where KIDS advanced for three days, in 218 of 285 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Aroon Indicator entered an Uptrend today. In 98 of 130 cases where KIDS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 75%.
The Tickeron Valuation Rating of 14 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.413) is normal, around the industry mean (4.142). P/E Ratio (-18.905) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (2.175) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. KIDS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KIDS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of orthopedic devices
Industry MedicalNursingServices